ArticleDiscover oncology2025
Mendelian randomization analysis reveals protective effects of LIFR and CXCL5 against breast cancer risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe causal connection between circulating inflammatory biomarkers and breast cancer susceptibility has not been definitively established.
methodsWe conducted a comprehensive Mendelian randomization investigation to examine potential causal links between inflammatory mediators and breast cancer development. Utilizing genome-wide association study data, we analyzed 91 circulating inflammatory markers in relation to breast cancer occurrence through a two-sample Mendelian randomization approach to determine causal relationships.
resultsOur analysis revealed that 13 inflammatory biomarkers demonstrated potential causal associations with breast cancer development (P < 0.05). However, after implementing false discovery rate (FDR) adjustment for multiple testing, only two inflammatory mediators maintained statistical significance (PFDR < 0.05): Leukemia inhibitory factor receptor (LIFR) concentrations and C-X-C motif chemokine 5 (CXCL5) concentrations, both showing inverse causal relationships with breast cancer risk.
conclusionThis investigation demonstrates that elevated LIFR and CXCL5 concentrations exhibit protective effects against breast cancer development, indicating an inverse causal relationship between these inflammatory markers and breast cancer susceptibility. These findings suggest that CXCL5 and LIFR may serve as protective biomarkers in breast cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.